Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Posts Earnings Results, Misses Expectations By $0.01 EPS

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01), Fidelity Earnings reports.

Shares of ATNM stock remained flat at $$0.35 on Tuesday. The company had a trading volume of 13,544,726 shares, compared to its average volume of 8,851,174. Actinium Pharmaceuticals has a 52-week low of $0.16 and a 52-week high of $0.62.

A number of analysts have commented on ATNM shares. Zacks Investment Research raised Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a report on Monday, June 22nd. Maxim Group started coverage on Actinium Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $1.50 price objective for the company. Finally, HC Wainwright initiated coverage on Actinium Pharmaceuticals in a report on Thursday, June 4th. They issued a “buy” rating and a $3.00 price objective for the company.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Further Reading: What are economic reports?

Earnings History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply